Le Lézard
Classified in: Health, Science and technology, Covid-19 virus

Global Natural Killer Cells Therapeutics Market (2022 to 2027) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts - ResearchAndMarkets.com


The "Natural Killer Cells Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

The global natural killer cells therapeutics market reached a value of US$ 2.1 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 5.1 Billion by 2027, exhibiting a CAGR of 15.94% during 2021-2027.

Companies Mentioned

Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Natural killer (NK) cells therapeutics target multiple pathogenic antigens with efficient cytotoxicity and reduce the risk of cytokine storms. They can be produced from a variety of sources without relying on patient-specific immune cells. At present, several strategies have been developed, such as ex vivo pre-conditioning with cytokines or small molecular drugs and engineering a chimeric antigen receptor (CAR) NK, which improve the efficacy of NK cells therapeutics.

Moreover, researchers are focusing on maximizing the therapeutic effects of allogeneic NK cells through robust expansion, enhanced targeting, and extended persistence of potent immune cells. This can also help unleash a strong and sustained anti-cancer immune-mediated attack.

A significant rise in the number of individuals with cancer, infectious diseases, and liver disorders represents one of the primary factors fueling the market growth. This can be attributed to unhealthy dietary patterns, lack of physical activities, growing air pollution, and the increasing number of individuals consuming alcohol and tobacco products.

Moreover, as the risk of developing cancer rises dramatically with age, the increasing geriatric population across the globe is acting as another growth-inducing factor catalyzing the demand for NK cells therapeutics. Apart from this, as the immune response of cancer patients is not adequate, health companies are developing novel methods and technologies to boost the immune response through allogeneic, off-the-shelf NK cell-based therapies.

Furthermore, there is a rise in the number of clinical studies that focus on tumor-targeted antibody strategies to enhance the therapeutic benefit of NK-cell-based therapy while minimizing risks and toxicities. In addition, governing agencies of numerous countries are funding financial schemes for cancer patients, which is creating a favorable outlook for the market.

Key Questions Answered in This Report:

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

4.1 Overview

4.2 Key Industry Trends

5 Global Natural Killer Cells Therapeutics Market

5.1 Market Overview

5.2 Market Performance

5.3 Impact of COVID-19

5.4 Market Forecast

6 Market Breakup by Therapeutics

7 Market Breakup by Application

8 Market Breakup by End User

9 Market Breakup by Region

10 SWOT Analysis

11 Value Chain Analysis

12 Porters Five Forces Analysis

13 Price Analysis

14 Competitive Landscape

14.1 Market Structure

14.2 Key Players

14.3 Profiles of Key Players

For more information about this report visit https://www.researchandmarkets.com/r/4e5eq7


These press releases may also interest you

at 22:33
The report titled "Identity Governance & Administration Market by Component (Services, Solution), Modules (Access Certification & Compliance Control, Access Management, Identity Lifecycle Management), Organization Size, Deployment, Vertical - Global...

at 20:09
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of QuidelOrtho Corporation between February 18, 2022 and April 1, 2024, both dates inclusive (the "Class Period") of the important June 11, 2024 lead...

at 19:30
Results  For the year ended January 31, 2024, the Company's revenues decreased by $139,027,000 to $578,945,000 compared to $717,972,000 recorded for the year ended January 31, 2023, a decrease of 19.4%. This decrease is mainly explained by the...

at 19:30
Lendistry announces today that it has been selected to administer the Entertainment Business Interruption Fund Program (BIF) to support small Los Angeles County businesses serving the entertainment industry. This program, created and funded through...

at 18:40
Rocky Mountain Liquor Inc. (the "Company" or "Rocky Mountain"), listed on the TSX Venture Exchange (the "Exchange"), today reported its financial results for the full year and fourth quarter ended December 31, 2023.KEY...

at 18:05
Guanajuato Silver Company Ltd. (the "Company" or "GSilver") announces a brokered, best-efforts Listed Issuer Financing Exemption private placement (the "Offering") consisting of units of the Company (the "Units") at a price of C$0.20 per Unit (the...



News published on and distributed by: